Latest news with #BostonScientificCorporation
Yahoo
16-05-2025
- Business
- Yahoo
Guidewires Market Size to Hit USD 1300 Million by 2032, Fueled by Demand for Minimally Invasive Procedures
The Global Guidewires Market Growth is Driven by RISING Incidences of Cardiovascular and Neurovascular Disorders, Coupled with Technological Innovations. Austin, May 16, 2025 (GLOBE NEWSWIRE) -- 'According to SNS Insider, the Guidewires Market size was valued at USD 814.90 million in 2023 and is projected to grow to USD 1300.49 million by 2032, representing a Compound Annual Growth Rate (CAGR) of 5.37% during the forecast period.' The guidewires market is a steadily growing market in the medical devices application sector, and it is the factors such as the prevalence of cardiovascular and neurovascular diseases and the growing preference for minimally invasive surgeries. New guidewire technology, including increased flexibility, torque control, and biocompatible materials, improves procedural success. It's also benefiting from an increasing number of interventional procedures and increasing utility across a broad range of medical sub-specialties - cardiology, urology, neurology, a Sample Report of Guidewires Market@ The U.S. Guidewires Market was estimated at USD 270.63 million in 2023 and is expected to reach USD 435.20 million by 2032, at a CAGR of 5.46% during the forecast period of 2024-2032 The United States dominates the North American guidewires market, capturing more than two-thirds of the regional market share in 2024. Its well-developed healthcare system, increased healthcare expenditure, and the existence of major medical device companies make it a dominant force. Increasing incidences of cardiovascular diseases, increased use of minimally invasive procedures, and favorable reimbursement policies further contribute to the market position. Major Players Analysis Listed in this Report are: Boston Scientific Corporation (Kinetix Guidewire, Fathom Steerable Guidewire) Medtronic plc (Intercept Core Wire Guide, Thunder Extra Support Guidewire) Abbott Laboratories (Hi-Torque Balance Middleweight Guidewire, Whisper MS Guidewire) Terumo Corporation (Glidewire Advantage Peripheral Guidewire, Runthrough NS Guidewire) B. Braun Melsungen AG (Certofix Guidewire, Introcan Safety Guidewire) Cardinal Health, Inc. (Guidant Guidewire, Cordis Emerald Guidewire) Cook Medical (Roadrunner PC Wire Guide, Lunderquist Extra-Stiff Wire Guide) Teleflex Incorporated (Spectre Guidewire, Arrow Guidewire) Asahi Intecc Co., Ltd. (Asahi PTCA Guide Wire, Asahi Peripheral Guide Wire) AngioDynamics, Inc. (Uni-Fuse Infusion System Guidewire, Soft-Vu Angiographic Guidewire) Merit Medical Systems, Inc. (InQwire Amplatz Guidewire, InQwire Diagnostic Guidewire) Nipro Medical Corporation (Nipro Guidewire, Nitinol Hydrophilic Guidewire) Gore Medical (Gore TIPS Set, Gore Hybrid Vascular Graft Guidewire) Biotronik SE & Co. KG (Coroflex ISAR NEO Guidewire, Galeo Pro Guidewire) Integer Holdings Corporation (VascuTrak PTA Dilatation Catheter Guidewire, MicroGuide Catheter Guidewire) Olympus Corporation (VisiGlide 2 Guidewire, UltraTrack Guidewire) Smiths Medical (JELCO Guidewire, Portex Guidewire) Stryker Corporation (Stryker Guidewire, Neuroform Atlas Stent System Guidewire) Vascular Solutions, Inc. (Langston Dual Lumen Catheter Guidewire, Twin-Pass Dual Access Catheter Guidewire) C.R. Bard, Inc. (Loma Vista Guidewire, TruGuide Guidewire) Guidewires Market Report Scope Report Attributes Details Market Size in 2023 US$ 814.90 million Market Size by 2032 US$ 1300.49 million CAGR CAGR of 5.37% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Key Growth Drivers The increasing incidence of cardiovascular and neurovascular diseases is a major driver for the guidewires market. Segment Analysis By Material, Stainless Steel Segment Dominates the Guidewires Market Stainless steel was the dominant segment of the guidewires market in 2023 due to its improved mechanical properties, including high tensile strength, excellent torque control, and kink resistance. These attributes make stainless steel guidewires ideal for complex interventional procedures, especially in cardiology and urology. Moreover, their affordability and easy availability make them a first choice in developed as well as developing countries. Stainless steel guidewires, too, provide consistent performance and durability, which are essential in precision-based minimally invasive procedures, thus cementing their stronghold in clinical practice in all specialty areas. By Product, Coronary Guidewires Segment Dominates the Guidewires Market In 2023, the coronary guidewires segment led the market for guidewires with a 42.56% market share due to the increasing global burden of cardiovascular disease, or coronary artery disease (CAD). Guidewires are central to percutaneous coronary interventions (PCI), which are increasingly utilized as less traumatic alternatives to open-heart surgery. Improvements in guidewire technology, including increased flexibility, steerability, and ability to cross lesions, also facilitate their universal application. Furthermore, increased awareness, increased cardiac care centers, and favorable reimbursement policies have greatly increased the volume of coronary interventions, fueling demand and further consolidating the hold of coronary guidewires on the international market. By Application, Cardiology Segment Dominates the Guidewires Market In 2023, the cardiology segment led the guidewires market with 26.22% market share because of the high incidence of cardiovascular diseases and the growing number of interventional cardiology procedures globally. Guidewires play a vital role in the navigation of intricate vascular pathways during procedures such as angioplasty and stent placement. The increase in demand for minimally invasive cardiac procedures, made possible by advanced imaging technology and device engineering, also drove cardiology applications. In addition, the rising aging population, lifestyle risk factors, and improved availability of specialty cardiac care have fueled procedure volumes, affirming cardiology's leadership in the global guidewires market. By End-User, Hospitals Segment Dominates the Guidewires Market In 2023, the guidewires market was dominated by the hospitals segment with 32.18% market share because they take center stage for conducting intricate diagnosis and interventional procedures, including cardiovascular, urological, as well as neurological interventions. With sophisticated infrastructure, trained healthcare practitioners, and integral diagnostic facilities, hospitals are becoming the foremost scenario for surgeries where guidewires are used. The rise in hospitalizations for acute and chronic conditions, along with growing investments in healthcare infrastructure, also increased guidewire usage further. Moreover, positive reimbursement policies and the presence of multidisciplinary care also lead to hospitals holding their top spot in the world guidewires market. Buy a Single-User PDF of Guidewires Market Analysis & Outlook Report 2024-2032@ North America Dominates the Guidewires Market, Asia-Pacific Expected to Register Fastest Growth North America leads the guidewires market with a 37.21% market share in 2023 its strong healthcare infrastructure, high usage of sophisticated medical technologies, and high healthcare expenditure. The market is supplemented by a strong density of market leaders, ongoing R&D activities, and elevated procedure volumes, especially for cardiovascular and neurovascular interventions. Good reimbursement policies and heightened consciousness toward minimally invasive procedures also fuel demand. The United States, for example, remains a key driver, driven by an expanding elderly population and an elevated incidence of chronic diseases. Asia-Pacific is expected to exhibit the fastest growth in the guidewires market with a 6.45% CAGR during the forecast period, due to enhanced healthcare infrastructure and expanding healthcare investments. Urbanization is happening at a fast pace, with rising healthcare access and higher cardiovascular disease burdens being key growth drivers. Government efforts to improve medical facilities and the growing presence of international medical device firms are also driving factors. Guidewires Market Segmentation By Material Nitinol Guidewire Stainless Steel Guidewire Hybrid Guidewire By Product Coronary guidewires Peripheral guidewires Urology guidewires Neurovascular guidewires By Application Cardiology Vascular Neurology Urology Gastroenterology Oncology Otolaryngology By End-User: Hospitals Diagnostic Centers Ambulatory Care Centers Research Laboratories & Academic Institutes Others Need Any Customization Research on Guidewires Market, Enquire Now@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of Target Diseases (2023) 5.2 Guidewire Usage Trends, by Specialty (2023 & Forecast 2024-2032) 5.3 Material Preference Trends (2023 & Forecast 2024-2032) 5.4 Healthcare Spending on Interventional Procedures (2023 & Forecast 2024-2032) 6. Competitive Landscape 7. Guidewires Market by Material 8. Guidewires Market by Product 9. Guidewires Market by Application 10. Guidewires Market by End-User 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Report Cardiac Catheters and Guidewires Market Analysis Cardiovascular Devices Market Insights Minimally Invasive Surgery Market Outlook Neurovascular Devices Market Growth Forecast Urology Devices Market Size, Share & Trends Analysis About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Yahoo
09-05-2025
- Business
- Yahoo
What Makes Boston Scientific Corporation (BSX) A Compelling Name Within The Large-Cap Medical Device Space?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices for use in various interventional medical specialties. The one-month return of Boston Scientific Corporation (NYSE:BSX) was 10.50%, and its shares gained 40.47% of their value over the last 52 weeks. On May 8, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $103.29 per share with a market capitalization of $153.116 billion. Baron Health Care Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2025 investor letter: "Boston Scientific Corporation (NYSE:BSX) is a global manufacturer of medical devices used in a broad range of interventional medical specialties. Shares contributed to performance. End markets are growing at an attractive 9%, with the company positioned well with its differentiated products in electrophysiology and structural heart. In particular, there has been increasing excitement around the emerging field of pulsed field ablation (PFA). Traditionally, doctors have used temperature-based methods (either hot or cold) to disable heart tissue responsible for irregular heartbeats; however, these methods may damage surrounding tissue. In comparison, PFA relies on electricity to damage aberrant tissue, and because different types of tissue have different electrical thresholds, the surrounding tissue can be selectively spared. Coupled with cost discipline and more than 50 basis points of annual operating margin expansion, we believe its double[1]digit EPS growth profile makes Boston Scientific a compelling name within the large-cap medical device universe." A surgeon examining a patient's brain in an operating room, paramedics nearby. Boston Scientific Corporation (NYSE:BSX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 96 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the third quarter which was 92 in the previous quarter. Boston Scientific Corporation's (NYSE:BSX) reported revenue of $4.663 billion, reflecting a 20.9% growth compared to Q1 2024. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of best medical device stocks to buy. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-04-2025
- Business
- Yahoo
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
Boston Scientific Corporation BSX posted first-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 33.9% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 11.9% and also exceeded the company's adjusted earnings per share guidance range of 66-68 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar). The quarter's adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others. Reported EPS for the first quarter was 45 cents, reflecting a 36.4% increase from the year-ago quarter figure. Revenues in the first quarter totaled $4.66 billion, up 20.9% year over year on a reported basis and 22.2% on an operational basis (at a constant exchange rate or CER). Organic growth, adjusted for foreign currency fluctuations and certain recent acquisitions and divestments, was 18.2%. The top line surpassed the Zacks Consensus Estimate by 2.3% and exceeded the company's forecast of 17%-19%. Following the earnings announcement, shares of BSX climbed 6% in pre-market trading today. In the first quarter, revenues rose 31.1% in the United States on a reported basis (same operationally). Reported revenues rose 5.5% in the Europe, Middle East and Africa (EMEA) region (up 7.9% operationally) and 8.2% in the Asia Pacific zone (up 10.6% operationally). Boston Scientific Corporation price-consensus-eps-surprise-chart | Boston Scientific Corporation Quote Reported revenues increased 4.4% in Latin America and Canada (up 14.1% operationally). Reported revenue growth in emerging markets was 6.5% (up 9.8% operationally). Boston Scientific recently reorganized its operational structure and aggregated its core businesses into two reportable segments — MedSurg and Cardiovascular. Both of these generate revenues from the sale of Medical Devices. MedSurg revenues in the first quarter were $1.58 billion, up 11.7% year over year on a reported basis (5.3% organically). Within this, the Endoscopy unit generated revenues of $673 million, up 5.5% organically. Urology revenues were $633 million, reflecting organic growth of 4.4%. The Neuromodulation business reported $271 million in revenues, highlighting a 6.8% rise organically year over year. The company generates maximum revenues from this segment. Revenues in the first quarter came up to be $3.09 billion, up 26.2% (reported) and 25.6% (organic) year over year. Within this, Cardiology business sales totaled $2.43 billion (up 31.2% year over year organically) in the first quarter. The Peripheral Interventions unit generated $656 million in sales, up 7.4%. The gross margin in the first quarter expanded 19 basis points (bps) year over year to 68.8%. There was a 20.2% rise in the cost of products sold to $1.45 billion in the reported quarter. Selling, general and administrative expenses rose 17.1% to $1.60 billion. Research and development expenses rose 21% to $443 million. Royalty expenses of $14 million, however, increased 40% year over year. The adjusted operating margin expanded 127 bps to 24.8% in the reported quarter. For 2025, Boston Scientific anticipates net sales to grow approximately 15-17% on a reported basis (earlier 12.5-14.5%) and nearly 12-14% on an organic basis (earlier 10-12%). The Zacks Consensus Estimate is currently pegged at $19.13 billion, indicating a 14.2% rise from the 2023 reported figure. Full-year adjusted EPS is expected in the range of $2.87-$2.94 (previously $2.80-$2.87). The Zacks Consensus Estimate for the same is currently pegged at $2.85. For the second quarter of 2025, revenue growth is projected in the range of approximately 17.5-19.5% on a reported basis (up 13-15% organically). Adjusted earnings are expected in the range of 71-73 cents per share. The Zacks Consensus Estimate for second-quarter earnings and revenues is pegged at 71 cents per share and $4.78 billion, respectively. Boston Scientific ended the first quarter of 2025 on a solid note, with both revenues and earnings beating the respective estimates. The performance reflected the strength of the company's product portfolio and the effectiveness of its highly engaged global team. Expansion of both margins in the quarter is impressive. Additionally, the raised sales and EPS guidance for the full year instils optimism. Among some notable developments, in March 2025, Boston Scientific announced an agreement to acquire SoniVie Ltd., the developer of the TIVUS Intravascular Ultrasound System. Earlier this month, the company completed the previously announced acquisition of Bolt Medical, Inc., the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease. All these bode well for the stock. Boston Scientific currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are AngioDynamics ANGO, Veeva Systems VEEV and Masimo MASI. AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today's Zacks #1 Rank stocks here. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite's 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%. Veeva Systems, sporting a Zacks Rank #1 at present, posted fourth-quarter fiscal 2025 adjusted EPS of $1.75, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $720.9 million surpassed the Zacks Consensus Estimate by 3.2%. VEEV has an estimated long-term earnings growth rate of 26.6% compared with the industry's 20.8% growth. The company's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.9%. Masimo, currently sporting a Zacks Rank #1, reported a fourth-quarter 2024 adjusted EPS of $1.80, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $600.7 million topped the Zacks Consensus Estimate by 0.8%. MASI has an estimated earnings yield of 3.5% for fiscal 2025 compared with the industry's 3.6% yield. The company's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.4%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Boston Scientific announces results for first quarter 2025
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago. "We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term." First quarter financial results and recent developments: Reported net sales of $4.663 billion, representing an increase of 20.9 percent on a reported basis, compared to the company's guidance range of 17 to 19 percent; 22.2 percent on an operational basis; and 18.2 percent on an organic basis, compared to the company's guidance range of 14 to 16 percent, all compared to the prior year period. Reported GAAP net income attributable to Boston Scientific common stockholders of $0.45 per share, compared to the company's guidance range of $0.43 to $0.45 per share, and achieved adjusted EPS of $0.75 per share, compared to the guidance range of $0.66 to $0.68 per share. Achieved the following net sales growth in each reportable segment, compared to the prior year period: MedSurg: 11.7 percent reported, 12.8 percent operational and 5.3 percent organic Cardiovascular: 26.2 percent reported, 27.6 percent operational and 25.6 percent organic Achieved the following net sales growth in each region, compared to the prior year period: United States (U.S.): 31.1 percent reported and operational Europe, Middle East and Africa (EMEA): 5.5 percent reported and 7.9 percent operational Asia-Pacific (APAC): 8.2 percent reported and 10.6 percent operational Latin America and Canada (LACA): 4.4 percent reported and 14.1 percent operational Emerging Markets4: 6.5 percent reported and 9.8 percent operational Commenced enrollment in the ELEVATE-PF clinical trial to evaluate the safety and effectiveness of the FARAFLEX™ Mapping and Pulsed Field Ablation (PFA) Catheter for treatment of persistent atrial fibrillation (AF). Began the OPTION-A clinical trial in the Asia-Pacific region to evaluate the safety and effectiveness of catheter ablation with the FARAPULSE™ PFA System and subsequent implant of the WATCHMAN™ Left Atrial Appendage Closure Device in a concomitant procedure. Published in The New England Journal of Medicine and presented as late-breaking science at the 2025 European Heart Rhythm Association annual meeting were results from the investigator-sponsored SINGLE SHOT CHAMPION clinical trial which demonstrated the FARAPULSE™ PFA System achieved superior effectiveness for the treatment of symptomatic paroxysmal AF versus the Arctic Front Advance™ cardiac cryoablation catheter (Medtronic). Presented late-breaking findings from the VITALYST Early Feasibility Study at the Technology and Heart Failure Therapeutics conference which demonstrated successful early experience with the investigational VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System in patients undergoing elective high-risk percutaneous coronary intervention. Published in JAMA Network Open real-world data demonstrating that patients with prostate cancer treated with SpaceOAR™ Hydrogel showed a 25% reduction in bowel disorder risk and a 46% decrease in procedures like colonoscopies four years post-radiation therapy. Completed the acquisition of Bolt Medical, Inc., the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease. Announced agreement to acquire SoniVie Ltd., the developer of the TIVUS™ Intravascular Ultrasound System, an investigational nerve denervation technology designed to treat hypertension — such as renal artery denervation in the kidneys — subject to customary closing conditions. 1. Operational net sales growth excludes the impact of foreign currency fluctuations. 2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. 3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. Net sales for the first quarter by business and region:Increase/(Decrease) Three Months Ended March 31,ReportedBasisImpact ofForeignCurrencyFluctuationsOperational BasisImpact ofCertainAcquisitions/DivestituresOrganicBasis (in millions) 2025 2024 Endoscopy $ 673 $ 6424.7 %1.2 %5.9 %(0.4) %5.5 % Urology 633 51323.5 %1.0 %24.5 %(20.1) %4.4 % Neuromodulation 271 2565.8 %0.9 %6.8 %— %6.8 %MedSurg 1,577 1,41211.7 %1.1 %12.8 %(7.5) %5.3 % Cardiology 2,429 1,87229.8 %1.4 %31.2 %— %31.2 % Peripheral Interventions 656 57314.4 %1.4 %15.8 %(8.4) %7.4 %Cardiovascular 3,085 2,44526.2 %1.4 %27.6 %(2.0) %25.6 % Net Sales $ 4,663 $ 3,85620.9 %1.3 %22.2 %(4.0) %18.2 % Increase/(Decrease) Three Months EndedMarch 31,ReportedBasisImpact ofForeignCurrencyFluctuationsOperational Basis (in millions) 2025 2024 U.S. $ 2,960 $ 2,25831.1 %— %31.1 %EMEA 846 8035.5 %2.4 %7.9 %APAC 701 6478.2 %2.4 %10.6 %LACA 155 1494.4 %9.6 %14.1 %Net Sales $ 4,663 $ 3,85620.9 %1.3 %22.2 %Emerging Markets4 $ 690 $ 6486.5 %3.3 %9.8 %Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP. Guidance for Full Year and Second Quarter 2025 The company estimates net sales growth for the full year 2025, versus the prior year period, to be approximately 15 to 17 percent on a reported basis and 12 to 14 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.86 to $1.93 and estimates adjusted EPS, excluding certain charges (credits), of $2.87 to $2.94. The company estimates net sales growth for the second quarter of 2025, versus the prior year period, to be in a range of approximately 17.5 to 19.5 percent on a reported basis, and 13 to 15 percent on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.45 to $0.47 and estimates adjusted EPS, excluding certain charges (credits), of $0.71 to $0.73. Conference Call InformationBoston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website. About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at and connect on LinkedIn and X. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the second quarter and full year 2025; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release. Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts. Use of Non-GAAP Financial InformationA reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release. CONTACT: Media: Chanel HastingsInvestors: Jonathan Monson508-382-0288 (office) 508-683-5450 (office)Media Relations Investor RelationsBoston Scientific Corporation Boston Scientific BSXInvestorRelations@ BOSTON SCIENTIFIC CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months Ended March 31, in millions, except per share data 2025 2024Net sales $ 4,663 $ 3,856 Cost of products sold 1,453 1,209 Gross profit 3,210 2,648Operating expenses: Selling, general and administrative expenses 1,597 1,364 Research and development expenses 443 366 Royalty expense 14 10 Amortization expense 219 214 Contingent consideration net expense (benefit) 5 17 Restructuring net charges (credits) 10 32,288 1,973 Operating income (loss) 921 675Other income (expense): Interest expense (82) (69) Other, net (34) 2 Income (loss) before income taxes 805 608 Income tax expense (benefit) 133 115 Net income (loss) 672 493 Net income (loss) attributable to noncontrolling interests (2) (1) Net income (loss) attributable to Boston Scientific common stockholders $ 674 $ 495Net income (loss) per common share - basic $ 0.46 $ 0.34 Net income (loss) per common share - diluted $ 0.45 $ 0.33Weighted-average shares outstanding Basic 1,477.2 1,468.4 Diluted 1,493.1 1,481.7Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS (Unaudited)Three Months Ended March 31, 2025 (in millions, except per share data) Gross Profit Operating Expenses Operating Income(Loss) OtherIncome (Expense) Income(Loss)BeforeIncomeTaxes NetIncome (Loss) Net Income(Loss)Attributable toNoncontrollingInterests Net Income(Loss)Attributable toBostonScientificCommonStockholders Impactper Share Reported $ 3,210 $ 2,288 $ 921 $ (116) $ 805 $ 672 $ (2) $ 674 $ 0.45 Non-GAAP adjustments:Amortization expense — (219) 219 — 219 189 2 187 0.13 Acquisition/divestiture-related net charges(credits) 89 (58) 148 1 149 154 — 154 0.10 Restructuring and restructuring-related netcharges (credits) 24 (24) 49 — 49 42 — 42 0.03 Investment portfolio net losses (gains) andimpairments — — — 8 8 7 — 7 0.00 EU MDR implementation costs 9 (4) 12 — 12 11 — 11 0.01 Deferred tax expenses (benefits) — — — — — 47 — 47 0.03 Adjusted $ 3,332 $ 1,982 $ 1,350 $ (106) $ 1,243 $ 1,121 $ 0 $ 1,121 $ 0.75Three Months Ended March 31, 2024 (in millions, except per share data) Gross Profit Operating Expenses Operating Income(Loss) OtherIncome (Expense) Income(Loss)BeforeIncome Taxes NetIncome (Loss) Net Income(Loss)Attributable toNoncontrolling Interests Net Income(Loss)Attributable toBostonScientificCommonStockholders ImpactperShare Reported $ 2,648 $ 1,973 $ 675 $ (67) $ 608 $ 493 $ (1) $ 495 $ 0.33 Non-GAAP adjustments:Amortization expense — (214) 214 — 214 184 2 182 0.12 Acquisition/divestiture-related net charges(credits) 10 (54) 64 (0) 64 77 — 77 0.05 Restructuring and restructuring-related netcharges (credits) 25 (21) 46 — 46 40 — 40 0.03 Investment portfolio net losses (gains) andimpairments — — — (14) (14) (11) — (11) (0.01) EU MDR implementation costs 9 (5) 14 — 14 12 — 12 0.01 Deferred tax expenses (benefits) — — — — — 37 — 37 0.02 Adjusted $ 2,692 $ 1,680 $ 1,012 $ (80) $ 932 $ 833 $ 1 $ 832 $ 0.56 An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATIONQ2 and FY 2025 GUIDANCE RECONCILIATIONS(Unaudited) Net SalesQ2 2025 EstimateFull Year 2025 Estimate(Low) (High)(Low) (High) Reported growth 17.5 % 19.5 %15.0 % 17.0 % Impact of foreign currency fluctuations 0.0 % 0.0 %0.5 % 0.5 % Operational growth 17.5 % 19.5 %15.5 % 17.5 % Impact of certain acquisitions/divestitures (4.5) % (4.5) %(3.5) % (3.5) % Organic growth 13.0 % 15.0 %12.0 % 14.0 % Earnings per ShareQ2 2025 EstimateFull Year 2025 Estimate(Low) (High)(Low) (High) GAAP results $ 0.45 $ 0.47$ 1.86 $ 1.93 Amortization expense 0.13 0.130.51 0.51 Acquisition/divestiture-related net charges (credits) 0.05 0.050.22 0.22 Restructuring and restructuring-related net charges (credits) 0.04 0.040.13 0.13 Other adjustments 0.04 0.040.16 0.16 Adjusted results $ 0.71 $ 0.73$ 2.87 $ 2.94 Amounts may not add due to rounding. Use of Non-GAAP Financial Measures To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes. To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively. To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules. Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance. We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance. View original content to download multimedia: SOURCE Boston Scientific Corporation Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025. "I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific," said Mike Mahoney, chairman and chief executive officer. "Dan is an exceptional leader, financial steward and teammate. He has been a critical leader on our global team as we have transformed the trajectory of BSX financial performance over many years. In addition to helping lead our highly differentiated financial performance, Dan has been central to building our strong values and culture. Throughout his career, he has been instrumental in developing talent within the financial organization. He and his team have overseen numerous strategic internal and external investment opportunities across our businesses since he assumed CFO responsibilities in 2014." Jon Monson, currently senior vice president, Investor Relations will succeed Brennan as executive vice president and CFO, effective June 30, 2025, reporting to Mahoney. Brennan and Monson will work closely together to ensure a smooth transition. In this role, Jon will be a member of the Executive Committee and have responsibility for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations and corporate business development. In addition to overseeing these functions, Jon will also drive capability and talent development across the company's global finance organization. "Jon is a proven leader who is known for his strategic mindset, diligent and thoughtful leadership and focus on high performance and continuous innovation," said Mahoney. "Having been with Boston Scientific for more than 25 years, he brings broad financial experience and expertise across many areas of the company which will serve him well in his new role." Prior to his current position leading investor relations, Jon held multiple roles of increasing responsibility across Boston Scientific finance, including five years as global controller and chief accounting officer and, prior to that, four years as vice president and controller of the company's Urology business. As global controller, he played a key leadership role in navigating the company through volatile financial periods, including the 2020 pandemic. He is a certified public accountant and earned his Bachelor of Arts degree in economics and accounting from the College of the Holy Cross. About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at and connect on LinkedIn and X. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our management transition plans, business plans and product performance, and financial performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document. CONTACT: Media: Chanel Hastings 508-382-0288 (office) Media Relations Boston Scientific Corporation Investors: Jonathan Monson 508-683-5450 (office) Investor Relations Boston Scientific Corporation BSXInvestorRelations@ View original content to download multimedia: SOURCE Boston Scientific Corporation Sign in to access your portfolio
